Altimmune Inc. announced that Stephen Durso will take over as Chief Executive Officer, succeeding Vipin Garg, effective immediately. The leadership change marks a significant transition for the company, which focuses on developing therapies for liver disease and immune modulation. Garg has served as CEO since 2018 and oversaw several key developments during his tenure.
The announcement comes alongside updates from other organizations in the biotech sector. Circle Therapeutics reported advancements in its clinical trials, NRG Pharmaceuticals disclosed new strategic partnerships, Ovid Therapeutics shared progress on its neurological treatment pipeline, and Tacalyx provided details on its immunotherapy research initiatives. These updates highlight ongoing activity across the industry as companies continue to pursue innovative solutions in healthcare.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For any suggestion and feedback, please contact us.
Date: December 2, 2025
發佈留言